REGN Regeneron Pharmaceuticals Inc

Price (delayed)

$946.87

Market cap

$103.93B

P/E Ratio

25.56

Dividend/share

N/A

EPS

$37.05

Enterprise value

$103.9B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The quick ratio has grown by 16% YoY and by 12% from the previous quarter
The equity has grown by 15% year-on-year and by 4.3% since the previous quarter
REGN's price to earnings (P/E) is 58% higher than its 5-year quarterly average of 16.2 and 21% higher than its last 4 quarters average of 21.2
Regeneron Pharmaceuticals's net income has decreased by 9% YoY

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
109.76M
Market cap
$103.93B
Enterprise value
$103.9B
Valuations
Price to book (P/B)
3.97
Price to sales (P/S)
7.7
EV/EBIT
24.32
EV/EBITDA
22.14
EV/Sales
7.92
Earnings
Revenue
$13.12B
EBIT
$4.27B
EBITDA
$4.69B
Free cash flow
$3.88B
Per share
EPS
$37.05
Free cash flow per share
$36.32
Book value per share
$238.4
Revenue per share
$122.94
TBVPS
$300.3
Balance sheet
Total assets
$33.08B
Total liabilities
$7.11B
Debt
$2.7B
Equity
$25.97B
Working capital
$16.06B
Liquidity
Debt to equity
0.1
Current ratio
5.69
Quick ratio
4.82
Net debt/EBITDA
-0.01
Margins
EBITDA margin
35.8%
Gross margin
86.2%
Net margin
30.1%
Operating margin
30.9%
Efficiency
Return on assets
12.6%
Return on equity
16.1%
Return on invested capital
15.7%
Return on capital employed
14.4%
Return on sales
32.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-0.12%
1 week
0.68%
1 month
1.44%
1 year
26.46%
YTD
7.81%
QTD
7.81%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$13.12B
Gross profit
$11.3B
Operating income
$4.05B
Net income
$3.95B
Gross margin
86.2%
Net margin
30.1%
Regeneron Pharmaceuticals's operating margin has decreased by 21% YoY and by 4% QoQ
The operating income fell by 15% YoY and by 4.1% QoQ
The net margin has decreased by 15% YoY
Regeneron Pharmaceuticals's net income has decreased by 9% YoY

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
25.56
P/B
3.97
P/S
7.7
EV/EBIT
24.32
EV/EBITDA
22.14
EV/Sales
7.92
REGN's price to earnings (P/E) is 58% higher than its 5-year quarterly average of 16.2 and 21% higher than its last 4 quarters average of 21.2
The company's EPS fell by 9% YoY
The equity has grown by 15% year-on-year and by 4.3% since the previous quarter
REGN's price to book (P/B) is 10% more than its last 4 quarters average of 3.6 but 3.2% less than its 5-year quarterly average of 4.1
The P/S is 22% higher than the 5-year quarterly average of 6.3 and 13% higher than the last 4 quarters average of 6.8
The revenue has increased by 8% YoY

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on invested capital has decreased by 25% YoY and by 7% QoQ
Regeneron Pharmaceuticals's return on equity has decreased by 21% YoY and by 4.2% QoQ
The return on assets has declined by 20% year-on-year and by 3.8% since the previous quarter
The company's return on sales fell by 19% YoY and by 4.1% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The quick ratio has grown by 16% YoY and by 12% from the previous quarter
REGN's total assets is up by 13% year-on-year and by 2.9% since the previous quarter
The debt is 90% less than the equity
REGN's debt to equity is down by 17% YoY and by 9% from the previous quarter
The equity has grown by 15% year-on-year and by 4.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.